New pill INX-315 takes on advanced breast and ovarian cancers

NCT ID NCT05735080

Recruiting now Disease control Sponsor: Incyclix Bio Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is to check safety, find the right dose, and see if it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INX-315 (an oral drug), sometimes combined with fulvestrant or abemaciclib
What this could lead to: If it works, this could provide a new treatment option for people with advanced breast or ovarian cancer that has stopped responding to standard therapies.
What could go wrong: This is an early first-in-human study, so safety and effectiveness are not yet proven. It may not work for all participants, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer Her2-receptor negative breast cancer hormone receptor-positive breast cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER BREAST CANCER BREAST CANCER, METASTATIC CCNE1 AMPLIFICATION HORMONE RECEPTOR POSITIVE TUMOR HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST METASTATIC CANCER OVARIAN CANCER SOLID TUMOR

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke Cancer Center/ DUMC
RECRUITING

Durham, North Carolina, 27705, United States
Emory Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Florida Cancer Specialists
RECRUITING

Orlando, Florida, 32827, United States
Fort Wayne Medical Oncology and Hematology
RECRUITING

Fort Wayne, Indiana, 46804, United States
Gabrail Cancer Research Center
RECRUITING

Canton, Ohio, 44718, United States
Georgia Cancer Center at Augusta University
RECRUITING

Augusta, Georgia, 30912, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Levine Cancer Institute (LCI)- Atrium Health
RECRUITING

Charlotte, North Carolina, 28204, United States
Mater Hospital
RECRUITING

South Brisbane, 4101, Australia
Next Oncology
RECRUITING

Dallas, Texas, 75039, United States
Next Oncology
RECRUITING

Houston, Texas, 77054, United States
Northwest Medical Specialties, PLLC
RECRUITING

Tacoma, Washington, 98405, United States
Oncology Consultants
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Peninsula and South Eastern Haematology & Oncology Group
RECRUITING

Frankston, Victoria, 3199, Australia
Peter MacCallum Cancer Center
RECRUITING

Parkville, Victoria, 3052, Australia
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States
UTSW Medical Center
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.